Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.40 |
| ▸ | MARS1 | P56192 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11258820 | 0.84 | ALDH1A1 (0.53) | PTGS2ALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL88823 | 0.84 | ALDH1A1 (0.61) | PTGS2ALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL14288599 | 0.83 | PTGS2 (0.47) | PTGS2ALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL586588 | 0.83 | MARS1 (0.42) | ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3086949 | 0.81 | GRIN2D (0.43) | ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL586319 | 0.81 | DAO (0.43) | PTGS2ALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL3933664 | 0.81 | MARS1 (0.41) | ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL603252 | 0.81 | ALDH1A1 (0.40) | ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3939805 | 0.81 | GRIN2D (0.43) | ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL12178225 | 0.80 | FFAR4 (0.40) | PTGS2ALDH1A1GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230145050-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | NodThera Limited (GB) | 2023-05-11 | — | — | US | disclosed |
| US-11518757-B2 | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | NodThera Limited (GB) | 2022-12-06 | — | — | US | disclosed |
| WO-2022120353-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| US-11136291-B2 | Antifungal compounds and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210147351-A9 | ANTIFUNGAL COMPOUNDS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210002261-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | NodThera Limited (GB) | 2021-01-07 | — | — | US | disclosed |
| US-20200140381-A1 | ANTIFUNGAL COMPOUNDS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-05-07 | — | — | US | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| US-10336748-B2 | Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-9518000-B2 | Bicyclo [2.2.1] acid GPR120 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160016880-A1 | BICYCLO [2.2.1] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| WO-2007145569-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| WO-2007145570-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145569-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | BACE1, BACE2, PSEN1 | PTGS2 3397/4885ALDH1A1 2961/4885GRIN2D 240/4885 |
| US-20230145050-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | NLRP3, NOD1, IL1B | PTGS2 1008/4885ALDH1A1 612/4885GRIN2D 4613/4885 |
| US-20210147351-A9 | ANTIFUNGAL COMPOUNDS AND USES THEREOF | ERG28, DPM1, CYP51A1 | PTGS2 1830/4885ALDH1A1 1944/4885GRIN2D 4102/4885 |
| US-10336748-B2 | Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | RORC, RORB, RORA | PTGS2 338/4885ALDH1A1 484/4885GRIN2D 1798/4885 |
| US-20160016880-A1 | BICYCLO [2.2.1] ACID GPR120 MODULATORS | GPR180, GPR88, GPBAR1 | PTGS2 388/4885ALDH1A1 2096/4885GRIN2D 364/4885 |
| US-20200140381-A1 | ANTIFUNGAL COMPOUNDS AND USES THEREOF | ERG28, DPM1, CYP51A1 | PTGS2 1830/4885ALDH1A1 1944/4885GRIN2D 4102/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | PTGS2 984/4885ALDH1A1 344/4885GRIN2D 326/4885 |
| US-11518757-B2 | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | NLRP3, NOD1, IL1B | PTGS2 1008/4885ALDH1A1 612/4885GRIN2D 4613/4885 |
| US-20210002261-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | NLRP3, NOD1, IL1B | PTGS2 1008/4885ALDH1A1 612/4885GRIN2D 4613/4885 |
| US-11136291-B2 | Antifungal compounds and uses thereof | ERG28, DPM1, CYP51A1 | PTGS2 1830/4885ALDH1A1 1944/4885GRIN2D 4102/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | PTGS2 1306/4885ALDH1A1 312/4885GRIN2D 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.